Browsing Tag
BioNTech SE
7 posts
Are AI-discovered vaccines the next big frontier in pharma?
AI-discovered vaccines are moving from hype to reality. See how Evaxion, BioNTech, DIOSynVax and Baseimmune are reshaping discovery—and why big pharma is buying.
Is BioNTech finally breaking out of its COVID shadow? The case for its oncology comeback
Discover how BioNTech is transforming from COVID-19 pioneer to oncology powerhouse, led by ADC success and mRNA innovations. Read more now.
BioNTech stock jumps 8.66% after DB-1303 meets primary endpoint in breast cancer trial
BioNTech stock surged after DB-1303 met its Phase 3 endpoint in HER2-positive breast cancer. Find out what this means for global oncology strategy.
CureVac stock surges as BioNTech announces strategic mRNA-focused acquisition
BioNTech acquires CureVac in a $1.25B all-stock deal to expand its mRNA cancer pipeline. Includes stock insights, premium terms, and investor sentiment.
Saia, BioNTech, and AppFolio stocks plunge amid trade war fallout
Explore why top U.S. stocks crashed on April 25, 2025, as tariffs, recession risks, and institutional selloffs rattled Wall Street. Read full sector analysis.
Wall Street rally: Pegasystems, Summit Therapeutics among top gainers as trade optimism lifts US stocks
Find out how Pegasystems, Summit Therapeutics, and Tempus AI surged on April 23, 2025, as tariff cuts and AI optimism drove major gains across US stock markets.
MediLink Therapeutics, BioNTech expand partnership with new $1.8bn agreement
MediLink Therapeutics (Suzhou) Co., Ltd., a prominent clinical-stage biotech company, has entered into a significant new strategic collaboration…